Ben Derman, MD

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.

Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

Ben Derman, MD, discussed the rationale for an ongoing clinical trial evaluating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.